Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Retained Earnings for 14 consecutive years, with -$151.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 5039900.0% year-over-year to -$151.2 million; the TTM figure through Mar 2026 stood at -$151.2 million (down 5039900.0% YoY), while the FY2025 annual figure was -$135.4 million, down 4515100.0% from the prior year.
• Retained Earnings retreated to -$151.2 million in Q1 2026 per PVLA's latest filing, from -$135.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at $342.9 million in Q3 2024 and bottomed at -$323.4 million in Q2 2024.
• Historically, Retained Earnings has averaged -$94.0 million across 5 years, with a median of -$123.4 million in 2025.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 391.24% — and 2026, when it tumbled 5039900.0%.
• Palvella Therapeutics' Retained Earnings stood at -$254000.0 in 2022, then sank by 122104.72% to -$310.4 million in 2023, then soared by 100.0% to $3000.0 in 2024, then plunged by 4515100.0% to -$135.4 million in 2025, then fell by 11.63% to -$151.2 million in 2026.
• Business Quant data shows PVLA's Retained Earnings at -$151.2 million in Q1 2026, -$135.4 million in Q4 2025, and $104000.0 in Q3 2025.